Press releases
- Press releases
- Browse
Press releases
The International Journal of Clinical Pharmacology and Therapeutics April 2009 Issue has published the latest peer-reviewed science on TDS-Testosterone. More
PharmaEssentia's third-generation interferon drug candidate P1101 (PEG-P-IFN-alpha-2b) for the treatment of hepatitis B and C, has received US FDA IND approval, with Phase I clinical trials in both Canada and Taiwan set to begin in the third quarter of 20 More
Vedolizumab is among the most promising Emerging Therapies with a novel mechanism of action, according to a new report from Decision Resources More
Two probiotic strains “GM-080” and “GMNL-33,” developed and marketed by GenMont Biotech Inc., (TWOTC: 3164) have been approved by regulatory agencies in China, and can now be used as additive ingredients to food products in that market. More
Protein drug development company Mycenax Biotech Inc. (GreTai, Taiwan: 4726) announced today that its rheumatoid arthritis and psoriasis drug TuNEX®, a biosimilar version of etanercept, has successfully completed a Phase I trial in South Korea and Phase I More
FDA ISSUED ORDERS TO SOLVAY AND AUXILIUM TO ADD BLACK BOX LABELS TO THEIR PRODUCTS AS NOTIFICATION TO USERS OF DANGER OF UNINTENDED TRANSFERENCE OF TESTOSTERONE TO FAMILY MEMBERS. TRANSDERMAL TECHNOLOGIES TDS-TESTOSTERONE'S RAPIDLY ABSORBED FORMULA WILL More
An HIV/AIDS vaccine developed by University of Western Ontario professor Chil-Yong Kang has reached "an important milestone" as it pushes towards the first phase of human trials. More
A drug that improves survival would earn a 50 percent patient share in the U.S. and a 40 percent patient share in Europe, according to a new report from Decision Resources More
The nature of pandemics makes cell-based Vaccines an ideal choice over Egg-Based Vaccines
New special report on Swine Flu now available from Decision Resources More
New special report on Swine Flu now available from Decision Resources More
Stalevo will retain Decision Resources’ gold-standard status through 2017 for Parkinson’s Disease, according to a new report from Decision Resource More
Related Reports
Market Research Reports provided by reports.iptechex.com
Dec 2006 - 8 pages - $1,295
Aug 2010 - 27 pages - $475
Aug 2010 - 27 pages - $475
Sep 2010 - 27 pages - $475
Sep 2010 - 27 pages - $475
Sep 2010 - 27 pages - $475
Sep 2010 - 27 pages - $475
Sep 2010 - 27 pages - $475
Sep 2010 - 27 pages - $475
Sep 2010 - 27 pages - $475
Your selection
- Year
- 2009 del
Browse By
- Industry sector
- Academic/Research
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Non-profit org./Government
- Pharmaceutical
- Research tools
- Service
- Therapeutic target
- Accident and Trauma
- Allergy
- Blood and forming organs
- Cardiovascular
- Central Nervous System
- Dermatological
- Endocrinology
- Gastrointestinal
- Genetic disorders
- Genito-urinary
- Hospital and Surgery
- Immune related disorders
- Infectious diseases
- Metabolism
- Musculoskeletal
- Oncology
- Oral Health
- Other therapeutic
- Respiratory
- Sensory organ
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us